IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

NCT03562871 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

BIOLOGICAL: IO102
BIOLOGICAL: pembrolizumab (Keytruda)
DRUG: Carboplatin (Carboplatin Kabi)
DRUG: Pemetrexed (Pemetrexed Alvogen)

Sponsor

IO Biotech

Collaborators

[object Object]